The high molecular weight mucin-like glycoprotein, DF3 (MUC1), is overexpressed in the majority of human breast cancers. Here we demonstrate that replication defective recombinant adenoviral vectors, containing the DF3 promoter (bp -725 to +31), can be used to express beta-galactosidase (Ad.DF3-betagal) and the herpes simplex virus thymidine kinase (HSV-tk) gene (Ad.Df3-tk) in DF3 positive breast carcinoma cell lines. In vivo experiments using breast tumor implants in nude mice injected with Ad.DF3-betagal demonstrated that expression of the beta-galactosidase gene is limited to DF3-positive breast cancer xenografts. Moreover, in an intraperitoneal breast cancer metastases model, we show that i.p. injection of Ad.DF3-tk followed by GCV treatment results in inhibition of tumor growth. These results demonstrate that utilization of the DF3 promoter in an adenoviral vector can confer selective expression of heterologous genes in breast cancer cells in vitro and in vivo.
Introduction
Gene therapy is a potentially novel approach to cancer treatment. In this context, transfer of suitable genetic material into a specific cell type (either tumor or host) can be used to alter the phenotype of the target cell. One such strategy is based on direct transfer of a "suicide gene" which encodes an enzyme such as herpes simplex thymidine kinase (HSV-tk)' that can activate a prodrug within tumor cells and thereby render the tumor cells sensitive to agents which are otherwise nontoxic to the cell. For example, ganciclovir (GCV) is a nucleoside that is nontoxic to mammalian cells, but is lethal after phosphorylation in cells that express HSV-tk (1) (2) (3) (4) . While gene therapy may provide a new therapeutic approach, clinical efficacy may require gene delivery systems which possess both high gene transduction efficiency and target cell specificity. 1 . Abbreviations used in this paper: Ad, adenovirus; CMV, cytomegalovirus; GCV, ganciclovir; HSV-tk, herpes simplex thymidine kinase; pfu, plaque-forming unit(s); X-gal, 5-bromo-4-chloro-3-indolyl P-Dgalactoside.
Human adenoviruses are non-enveloped double-stranded DNA viruses with a genomic size of 36 kb (5, 6) . The El gene-deleted adenoviruses are replication defective and can be grown in a packaging cell line transformed with the Ela and Elb genes (7) . Adenoviral vectors deleted at the El and E3 regions are capable of accommodating DNA inserts up to 8 kb (8, 9) . Moreover, adenovirus-mediated gene transfer is a highly efficient means for delivery of genetic material into a wide spectrum of cells both in vitro and in animals. Although recombinant adenoviruses hold promise for in vivo gene therapy and are being tested clinically (10) , one of the limitations of this vector system for cancer therapy may be the nonspecific transduction of therapeutic genes into nontarget cells. One strategy to circumvent this limitation would be to use a tumor-tissue specific/selective promoter or enhancer to direct the expression of a therapeutic gene in the desired target cells.
DF3 antigen (also designated MUC1 and episialin) is a member of a family of high molecular weight glycoproteins which are aberrantly overexpressed in most human breast cancers. We have previously shown that monoclonal antibody mAb DF3, prepared against a membrane-enriched extract of a human breast carcinoma metastatic to liver, reacts with over 75% of primary human breast carcinomas (11) . Other studies have shown that overexpression of the DF3 gene in human MCF-7 (12) and ZR-75 breast cancer cells (13) is regulated at the transcriptional level. Recent cloning and characterization of the 5' flanking region of DF3 gene has demonstrated that the DF3 gene expression is mainly regulated by sequences between positions -598 and -485 bp upstream to the transcription start site (14) .
In the present work, we describe the construction of replica- (Fig. 2, A-C) , whereas little if any 63-galactosidase activity could be detected in similarly infected Hs578Bst, MDA-MB23 1 and T98G cells (Fig. 2, D-F) . In contrast, all of these cell lines showed strong expression of O-galactosidase when infected with Ad.CMV-,/gal (Fig. 2, G-I there is a correlation between DF3 expression and capability of these cells to express /3-galactosidase after Ad.DF3-f6gal infection, we examined the presence of DF3 antigen in MCF-7, ZR-75-1, and Hs578Bst cells by FACS analysis. MCF-7 and ZR-75-1 cells exhibited strong reactivity with mAb DF3, a monoclonal antibody against DF3 antigen, while little if any mAb DF3 binding was detectable with Hs578Bst cells (Fig. 3 A) (Fig. 4) . Moreover, Ad.DF3-tk transduction conferred sensitivity of both MCF-7 and ZR-75 cells to GCV (Fig. 4, A and B) , while nontransduced cells or cells transduced with Ad.CMV-f3gal or Ad.DF3-figal (data not shown) were insensitive to GCV (Fig. 4) . As previously demonstrated (19, 20) , similar results were obtained when cells were exposed to GCV for 6-7 d or to GCV for 24 h followed by incubation for 5-6 d in media (data not shown). The degree of Ad.DF3-tkmediated GCV sensitivity was comparable to that obtained with Ad.DF3-tk. In contrast, when Ad.DF3-tk and Ad.CMV-tk were used to in infect DF3-negative Hs578Bst epithelial cells, only Ad.CMV-tk infected cells were sensitive to GCV (Fig. 4 C) .
In Similar results were obtained in three separate experiments.
the surrounding normal tissue (Fig. 5 B) . In contrast, when
Ad.DF3-/3gal was injected into DF3-negative MDA-MB23 1 tumors grown in nude mice, there was no detectable /3-galactosidase staining along the needle tract (Fig. 5 C) . Intramuscular injections of Ad.DF3-/3gal also resulted in no detectable /3-galactosidase activity (Fig. 5 D) , while similar injections of
Ad.CMV-tigal into skeletal muscle was associated with strong expression of /3-galactosidase (Fig. 5 E) . of the liver, spleen, and lung were stained for 63-galactosidase activity. Systemic injection of Ad.CMV-p6gal resulted in expression of /3-galactosidase in the liver parenchyma, in the splenic red pulp, and diffusely in the lung (Fig. 6 A) . By contrast, there was no detectable /3-galactosidase staining in these tissues in mice injected with Ad.DF3-figal. Several foci of /3-galactosidase staining (representing < 0. 1% of cells in tumor cross sections) were detected in MCF-7 tumors of animals that received systemic Ad.DF3-,3gal (Fig. 6 B) . However, i.p. injection of Ad.DF3-fogal into mice bearing intraperitoneal MCF-7 tumor was associated with extensive expression of 6-galactosidase in the tumor (Fig. 6 C) . Treatment of intraperitoneal breast tumor. To evaluate the therapeutic efficacy of Ad.DF3-tk in human DF3-positive breast cancer cells in vivo, nude mice were inoculated i.p. with MCF-7 cells. These mice developed tumor masses throughout the peritoneal cavity and 2-4 ml of bloody ascites that contained tumor cells (Fig. 7 A) . MCF-7 tumor bearing mice were treated with Ad.DF3-f6gal + saline, Ad.DF3-,/gal + GCV, Ad.DF3-tk + saline and Ad.DF3-tk + GCV. Adenoviruses were injected i.p. on day 4 after tumor inoculation. GCV or saline injections were then administered on day 7 after tumor inoculation. Untreated mice and those treated with Ad.DF3-/3gal or Ad.DF3-tk + saline developed multiple intraperitoneal tumors with bloody ascites. In contrast, there was no grossly identifiable tumor mass or only a few small tumor clusters with no apparent ascites in the Ad.DF3-tk/GCV-treated mice (Fig. 7, B and C) . In other studies, Ad.DF3-tk (2 X 109 pfu) was administered intravenously by tail vein to mice with intraperitoneal tumors. The finding that treatment of these animals with GCV had no detectable therapeutic effect is in concert with the limited transduction of tumor cells after systemic administration of the vector (as shown in Fig. 6 B) .
Discussion
The results presented here demonstrate that the DF3 gene promoter in the context of a recombinant adenoviral vector can Currently available in vivo gene delivery systems generally lack target cell specificity. Nonviral approaches, such as ligand-DNA complexes mediated gene transduction through receptor endocytosis have been reported to deliver genes through asialoglycoprotein receptors (21, 22) . This approach, however, is largely hindered by the relatively low gene transduction efficiency due to the endosomal/lysosomal trapping of the DNA complex. Although other approaches such as the use of DNA liposome complexes (23, 24) and direct injection of DNA (25) have been applied for direct in vivo gene transfer, they are also limited by relative low gene transduction or restricted target tissues. Retroviral vectors have been used extensively for gene transfer, particularly for ex vivo gene therapy (26) (27) (28) (29) 
IL_
The similar findings obtained in our studies further support the present limitations in using adenoviral vectors for the treatment of a disseminated tumor. These findings also support the potential need for promoters that are not activated in hepatocytes.
To date, only a few tumor tissue-specific or -selective DNA regulatory sequences have been identified. Moreover, most studies of selective promoters to target tumor cells were performed in cell culture or ex vivo models. Selective expression in melanoma cells has been reported using plasmids containing the promoters of the genes encoding tyrosinase and tyrosinase related proteins (36, 37). The promoter of the ax-fetoprotein gene (38) , the promoter of the oncogene ERBB2 (39) , and recently the enhancer sequence (-598 to -485) of the DF3 gene (20) have been explored in the context of retroviral vectors to direct expression of prodlrug activating enzymes and to confer selective tumor killing in a number of cancer cell lines in vitro. However, to our knowledge, there are no previous reports of using a tumor-selective promoter in the context of an adenovirus vector to selectively kill tumor cells in vivo. In the present studies, we have demonstrated an efficient and selective approach to target expression of heterogous genes in DF3-positive breast cancer cells. Currently, recombinant adenoviral vectors containing the DF3 promoter and other candidate therapeutic genes including cytochrome P450 (40, 41) , and cytosine deaminase (42, 43) are being developed.
